Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 6/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921697 | 0.90 | HTR4 (0.38) | HTR4PDE7AHRH3ALDH1A1 | |
| SCHEMBL17185039 | 0.90 | HTR4 (0.38) | HTR4PDE7AHRH3POLBHSD17B10 | |
| SCHEMBL5921688 | 0.90 | HTR4 (0.38) | HTR4PDE7AHRH3ALDH1A1 | |
| SCHEMBL22208127 | 0.87 | POLB (0.46) | PDE7AHRH3POLBHSD17B10SIGMAR1 | |
| SCHEMBL854179 | 0.86 | PDE7A (0.46) | PDE7AHRH3POLBHSD17B10SIGMAR1 | |
| SCHEMBL854180 | 0.86 | PDE7A (0.46) | PDE7AHRH3POLBHSD17B10SIGMAR1 | |
| SCHEMBL30098868 | 0.84 | HTR4 (0.42) | HTR4PDE7AHRH3POLBHSD17B10 | |
| SCHEMBL2012289 | 0.84 | CD38 (0.38) | HTR4PDE7AHRH3POLBHSD17B10 | |
| SCHEMBL23573288 | 0.83 | POLB (0.56) | HRH3POLBHSD17B10SIGMAR1 | |
| SCHEMBL3369574 | 0.83 | POLB (0.51) | HRH3POLBHSD17B10SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901315-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140073799-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| EP-1775298-B1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-2433943-A1 | Thienopyrazole derivatives having PDE7 inhibitory activity | Daiichi Sankyo Company, Limited (JP) | 2012-03-28 | — | — | EP | disclosed |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073799-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | PDE7A, PDE7B, PDE3B | HTR4 973/4885PDE7A 1/4885HRH3 33/4885 |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | PDE7A, PDE7B, PDE3B | HTR4 973/4885PDE7A 1/4885HRH3 33/4885 |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | PDE7A, PDE7B, PDE3B | HTR4 973/4885PDE7A 1/4885HRH3 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.